Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Cisplatin-Unfit Urothelial Cancer
NCT03891238Phase 2Completed
- Sponsor
- Consorzio Oncotech
- Start
- Feb 2019
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in urothelial carcinoma (UC), sponsored by Consorzio Oncotech. Primary endpoint: Overall Survival at 2 years. Started Feb 2019; status: completed.
02
Drugs
avelumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03891238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891238.